Cardiogen

Cardiogen is a synthetic four-amino-acid peptide, AEDR, discussed as a heart bioregulator. People seek easier exertion, quieter heart symptoms or protection during aging and hard training. Reports range from better exercise tolerance to no noticeable change and higher resting heart rate. Those experiences do not establish heart repair, and the circulating amounts and calendars disagree.

AEDR identifies four linked amino acids. Ala-Glu-Asp-Arg is the full sequence. The originating patent describes a synthetic peptide and animal cardiac experiments. A heart-associated research label does not establish targeted delivery or human heart repair. US7662789B2 — Peptide substance restoring myocardium function (Animal context · Accessed 2026-09-30)

A pure peptide and a heart extract are different products. The existing discussion distinguishes synthetic Cardiogen from Chelohart-style animal-tissue complexes. Capsules, under-the-tongue products, subcutaneous injections beneath the skin and less-common intramuscular injections appear. Their labeled milligrams cannot be treated as equivalent exposure. Intraperitoneal administration belongs to animal research, not this human community account.

Source context — US7662789B2 — Peptide substance restoring myocardium function: Applicant's patent experiments, not peer-reviewed human clinical outcomes; patent claims do not establish approval or efficacy.

Easier high-intensity exercise in one account. A gym user in a vendor-branded subreddit describes improved HIIT tolerance, but no clear resting-heart-rate or heart-rate-variability change. Training itself complicates attribution; the post gives no dose or route. Feeling fitter does not show repaired myocardium, the heart muscle. Cardiogen — HIIT experience and unchanged RHR (Personal report · Accessed 2026-09-30)

Heart-symptom reports need their follow-ups. One BodyHackGuide commenter initially describes calmer arrhythmia, then says symptoms persist and they cannot tell whether Cardiogen helped their premature ventricular contractions, or extra heartbeats. Another reports fewer angina episodes but no improvement in a conduction problem. Neither account establishes treatment of heart disease. Cardiogen — dose, symptom and cycling discussion (Personal report · Accessed 2026-09-30) · Later arrhythmia follow-up — uncertain Cardiogen benefit (Personal report · Accessed 2026-09-30)

Prevention is a motive, not an observable result. A third-week user taking Prostamax alongside Cardiogen reports no distinct Cardiogen effect. Their preventive motive followed a friend's heart attack. The existing record also preserves quieter exertion and post-PED recovery hopes; feeling nothing cannot prove protection or a failed dose. Cardiogen — third-week nonresponse clarified (Personal report · Accessed 2026-09-30)

A higher resting heart rate is not reassurance that repair is happening. The bedtime reporter moved use earlier and thought it helped, but later stopped on day twelve. HGH and SS-31 co-use and uncertain product identity prevent a clean causal conclusion. Another commenter reports lower heart rate and blood pressure with morning use. Opposing accounts do not establish a predictable response. Cardiogen Bioregulator - high rhr (Personal report · Accessed 2026-09-30)

Source context — Cardiogen — HIIT experience and unchanged RHR: Vendor-branded setting; unknown sponsorship; training confounder; no dose/route or objective improvement supplied. Category explanations are user claims.

Source context — Cardiogen — dose, symptom and cycling discussion: Routes unstated in cited comments; self-reported diagnoses; community has commercial-directory promotion. Different commenters and endpoints must remain distinct.

Source context — Later arrhythmia follow-up — uncertain Cardiogen benefit: Same person as earlier calmer-arrhythmia report; diagnosis revised in their own words, not independently confirmed. BPC-157 efficacy assertion is not accepted as clinical fact.

Source context — Cardiogen — third-week nonresponse clarified: Crosspost of BodyHackGuide's question, but separate commenter; not an independent copy of the original question. No dose/route stated.

Source context — Cardiogen Bioregulator - high rhr: Self-report; route unspecified; co-use and uncertain identity; no independent verification. Replies about other peptides are not Cardiogen dosing evidence.

Oral charts: 10–20 mg daily, usually short courses. The existing record includes 10 mg/day for ten days (100 mg total), 20 mg/day for ten days (200 mg), and 20 mg/day for twenty days. Some summaries instead say 10–20 mg per cycle; that wording cannot be silently changed to per day. Oral and sublingual labels remain product-specific.

Lower injection charts: 200–500 mcg or 0.2–2 mg daily. These overlapping subcutaneous bands are preserved separately. An opened community guide repeats 0.2–2 mg once daily for 10–20 days without a trial-established dose. A Reddit user reports 2 mg/day at bedtime but leaves the route unstated. Cardiogen Dosage: Community Protocols Explained (Community guide · Accessed 2026-09-30) · Cardiogen Bioregulator - high rhr (Personal report · Accessed 2026-09-30)

Higher charts conflict with those lower bands. Existing writeups include mixed oral/injection 1–5 mg/day, IM/SubQ 5–10 mg/day for 5–10 days, 10 mg every other day, and 5–20 mg/day for 10–30 days. These are separate secondary-chart traditions, not successive steps or safe ceilings.

Intermittent and longer patterns are different again. The original includes 10–20 mg SubQ every 3–7 days for 2–4 weeks, 10 mg/day oral or SubQ for 4–6 weeks, and calculator ramps from 200 to 500 mcg/day over twelve weeks. A forum reply separately repeats 1–2 mg/day for sixty days or ambiguously worded 5 mg split twice weekly. No equivalence follows. Cardiogen — Peptide Critic forum reply (Secondhand community claim · Accessed 2026-09-30)

Personal course totals are not dosing trials. BodyHackGuide reports include 1 mg/day rising to 2 mg/day and a separate 60 mg course reaching 3 mg nightly. Routes are unstated in those comments. Amounts alone do not resolve identity, absorption or safety. Cardiogen — dose, symptom and cycling discussion (Personal report · Accessed 2026-09-30)

Source context — Cardiogen Dosage: Community Protocols Explained: Commercially connected aggregator with vendor-pricing links; community convention, no trial-defined dose. Reconstitution and purchase material excluded.

Source context — Cardiogen Bioregulator - high rhr: Self-report; route unspecified; co-use and uncertain identity; no independent verification. Replies about other peptides are not Cardiogen dosing evidence.

Source context — Cardiogen — Peptide Critic forum reply: Secondhand protocol, not a use log. Page says topic deleted but returned these bodies; scope limited to exposed text. 5 mg split twice weekly is ambiguous about total/per-use amount.

Source context — Cardiogen — dose, symptom and cycling discussion: Routes unstated in cited comments; self-reported diagnoses; community has commercial-directory promotion. Different commenters and endpoints must remain distinct.

First-night changes and day-nine impressions both appear. The 2 mg/day bedtime user describes elevated resting heart rate overnight. Another reports a change around day nine; a third-week user feels no distinct benefit. Older day-4–10 and day-10–20 checkpoints remain reported expectations, not a reliable response clock. Cardiogen Bioregulator - high rhr (Personal report · Accessed 2026-09-30) · Cardiogen — dose, symptom and cycling discussion (Personal report · Accessed 2026-09-30) · Cardiogen — third-week nonresponse clarified (Personal report · Accessed 2026-09-30)

No dependable single-dose or post-course duration. The existing account describes hoped-for residual comfort or endurance over days to weeks, including a 2–8-week post-course window. These are downstream-effect stories, not blood-level measurements. Opened reports do not establish a consistent lasting benefit; continuing or returning symptoms also appear. Later arrhythmia follow-up — uncertain Cardiogen benefit (Personal report · Accessed 2026-09-30)

Seconds and hours are competing claims, not dependable human measurements. The original preserves 30–75-second estimates and multi-hour bioregulator estimates. An opened dosing site repeats a few hours without a Cardiogen-specific PK study and also prints the wrong sequence. Neither figure supports an accumulation calculation. Daily or weekly schedules cannot establish how fast AEDR clears. Cardiogen Dosage, Reconstitution & Mixing Trends (Community guide · Accessed 2026-09-30)

Source context — Cardiogen Bioregulator - high rhr: Self-report; route unspecified; co-use and uncertain identity; no independent verification. Replies about other peptides are not Cardiogen dosing evidence.

Source context — Cardiogen — dose, symptom and cycling discussion: Routes unstated in cited comments; self-reported diagnoses; community has commercial-directory promotion. Different commenters and endpoints must remain distinct.

Source context — Cardiogen — third-week nonresponse clarified: Crosspost of BodyHackGuide's question, but separate commenter; not an independent copy of the original question. No dose/route stated.

Source context — Later arrhythmia follow-up — uncertain Cardiogen benefit: Same person as earlier calmer-arrhythmia report; diagnosis revised in their own words, not independently confirmed. BPC-157 efficacy assertion is not accepted as clinical fact.

Source context — Cardiogen Dosage, Reconstitution & Mixing Trends: Commercial-style dosage summary gives Lys-Glu-Asp-Pro rather than AEDR; no located PK measurement in inspected text. Used only to describe and reject unreliable circulated claims.

10–20 days on; repeat every 3–6 months in traditional charts. The original includes 10-day oral courses, sometimes 20–30 days, spring/fall calendars and two-to-four yearly repeats. The opened guide also describes 10–20 days. A gym user's two-to-three yearly convention is not evidence of retained benefit or a proven off period. Cardiogen Dosage: Community Protocols Explained (Community guide · Accessed 2026-09-30) · Cardiogen — HIIT experience and unchanged RHR (Personal report · Accessed 2026-09-30)

Month-long, sixty-day and twelve-week accounts coexist. Fresh comments describe roughly every-other-month cycling or one month on/three months off. Peptide Critic repeats sixty-day blocks three times yearly. Older charts extend 2–6 weeks or twelve weeks, sometimes matching on/off blocks or multi-week breaks. Receptor-reset explanations and preventive/aggressive labels are lore, not validated maintenance rules. Cardiogen — dose, symptom and cycling discussion (Personal report · Accessed 2026-09-30) · Cardiogen — Peptide Critic forum reply (Secondhand community claim · Accessed 2026-09-30)

Source context — Cardiogen Dosage: Community Protocols Explained: Commercially connected aggregator with vendor-pricing links; community convention, no trial-defined dose. Reconstitution and purchase material excluded.

Source context — Cardiogen — HIIT experience and unchanged RHR: Vendor-branded setting; unknown sponsorship; training confounder; no dose/route or objective improvement supplied. Category explanations are user claims.

Source context — Cardiogen — dose, symptom and cycling discussion: Routes unstated in cited comments; self-reported diagnoses; community has commercial-directory promotion. Different commenters and endpoints must remain distinct.

Source context — Cardiogen — Peptide Critic forum reply: Secondhand protocol, not a use log. Page says topic deleted but returned these bodies; scope limited to exposed text. 5 mg split twice weekly is ambiguous about total/per-use amount.

Heart-plus-vessel and multi-organ stacks blur credit. Vesugen is paired with Cardiogen in cardiovascular calendars, without a tested component ratio. Older combinations include Epitalon, Pinealon, Thymalin, Thymogen, Cortagen, Vilon and Cartalax; recovery circles add BPC-157/TB-500, while longevity stacks add SS-31, MOTS-c, NAD precursors, CoQ10 or omega-3. PED/PCT framing and synthetic-then-extract sequencing remain discussion, not demonstrated synergy. Cardiogen — Peptide Critic forum reply (Secondhand community claim · Accessed 2026-09-30)

Heart + vessels classic: Cardiogen + Vesugen (KED) — heart-muscle bioregulator paired with vascular/endothelial bioregulator for full CV longevity talk; often same short-course calendar (e.g. ~10–20 days each) with no fixed mg:mg trial ratio. [community]

Source context — Cardiogen — Peptide Critic forum reply: Secondhand protocol, not a use log. Page says topic deleted but returned these bodies; scope limited to exposed text. 5 mg split twice weekly is ambiguous about total/per-use amount.

A higher resting heart rate is not reassurance that repair is happening. The bedtime reporter moved use earlier and thought it helped, but later stopped on day twelve. HGH and SS-31 co-use and uncertain product identity prevent a clean causal conclusion. Another commenter reports lower heart rate and blood pressure with morning use. Opposing accounts do not establish a predictable response. Cardiogen Bioregulator - high rhr (Personal report · Accessed 2026-09-30)

Other side effects remain poorly characterized. Existing reports include injection-site irritation, headache, fatigue, blood-pressure fluctuation and occasional digestive discomfort. Long-term safety and drug interactions lack reassuring evidence here. Tumor-growth and angiogenesis concerns are theoretical; opposite findings in different tissues cannot prove cancer safety. Levdik and Knyazkin 2009 — M-1 sarcoma in rats, PMID 20396706 (Animal context · Accessed 2026-09-30)

Do not let a peptide story delay cardiac care. The preserved caution remains: Cardiogen is not a substitute for chest-pain, arrhythmia, heart-failure, post-heart-attack or uncontrolled-hypertension evaluation. Emergency symptoms need medical care. Uncertain interactions do not justify changing cardiac medicines, and a laboratory certificate cannot guarantee the contents or clinical safety of an online product.

Source context — Cardiogen Bioregulator - high rhr: Self-report; route unspecified; co-use and uncertain identity; no independent verification. Replies about other peptides are not Cardiogen dosing evidence.

Source context — Levdik and Knyazkin 2009 — M-1 sarcoma in rats, PMID 20396706: Abstract only; dose/route details not available in abstract. Does not establish human cancer treatment or safety.